Olema Pharmaceuticals, Inc. - 8-K Filing
Olema Pharmaceuticals announced preliminary data from its Phase 1 study of OP-3136, a KAT6 inhibitor, showing no dose-limiting toxicities and tumor shrinkage in 13 out of 19 evaluable patients. The drug was well-tolerated with most adverse events being grade 1 or 2; key side effects included dysgeusia (81%), anemia (38%), and neutropenia (34%). These findings will be presented at the ASCO Annual Meeting on May 30, 2026. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $OLMA